A Practitioner’s Guide to Prescribing Tiagabine for Adults with Intellectual Disabilities
We developed this tiagabine guideline using drug prescribing information and reviewing the available literature on relevant neuropsychiatric disorders in populations without intellectual disabilities because of the dearth of available literature on the population with intellectual disabilities. This guideline includes indications; contraindications; assessments prior to and during treatment; dosing with particular focus on dosing modifications required by drug–drug interactions, personal characteristics; and adverse drug reactions. The procedures contained in this guideline may not fully account for all of the possible risks of treatment in this population because of the limited studies available; thus, there will be a need to periodically update this guideline as new information becomes available. Nevertheless, we believe that this guideline provides a useful resource for clinicians who treat epilepsy in adult individuals with intellectual disabilities. A tiagabine drug utilization review that summarizes this guideline is described.
KeywordsSuicidal Ideation Status Epilepticus Intellectual Disability Suicide Risk Nonconvulsive Status Epilepticus
- Inc, C. (2010). Gabitril-tiagabine hydrochloride tablet (prescribing information). Frazer, PA: Cephalon Inc.Google Scholar
- Chmielewska, B., & Stelmasiak, Z. (2002). Effectiveness of adjunctive therapy with tiagabine in mentally disabled patients with epilepsy. Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina, 57, 226–236.Google Scholar
- Lacy, C. F., Armstrong, L. L., Goldman, M. P., & Lance, L. L. (2009). Drug information handbook (18th ed.). Hudson, OH: Lexi-Comp Inc.Google Scholar
- Merrick, J., Merrick, E., Lunsky, Y., & Kandel, I. (2006). A review of suicidality in persons with intellectual disability. The Israel Journal of Psychiatry and Related Science, 43, 258–264.Google Scholar
- Pereira, J., Marson, A. G., Hutton, J. L. (2002). Tiagabine add-on for drug-resistant partial epilepsy. The Cochrane Database Systematic Review 3:CD001908.Google Scholar
- US Department of Mental Health and Human Services. (2008). Statistical review and evaluation: Antiepileptic drugs and suicidality. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf Accessed 5.04.2011.
- Young, A. H., Geddes, J. R., Macritchie, K., Rao, S. N., Vasudev, A. (2006a). Tiagabine in the maintenance treatment of bipolar disorders. The Cochrane Database Systematic Review 3:CD005173.Google Scholar
- Young, A. H., Geddes, J. R., Macritchie, K., Rao, S. N., Vasudev, A. (2006b). Tiagabine in the treatment of acute affective episodes in bipolar disorder: Efficacy and acceptability. The Cochrane Database Systematic Review 3:CD004694.Google Scholar